Test Code AK5IC Adenylate Kinase 5 (AK5) IgG, Tissue Immunofluorescence, Spinal Fluid (Non-Orderable)
Specimen Required
Only orderable as part of a profile. For more information see:
-DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Useful For
Only orderable as part of a profile. For more information see:
DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Evaluation of patients suspected to have autoimmune encephalitis using spinal fluid specimens
Reporting adenylate kinase 5 tissue immunofluorescence results as part of a profile
Reflex Tests
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| AK5CC | AK5 Ab CBA, CSF | No | No |
| AK5TC | AK5 Ab IFA Titer, CSF | No | No |
Method Name
Only orderable as part of a profile. For more information see:
-DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Indirect Immunofluorescence Assay (IFA)
Reporting Name
AK5 Ab IFA, CSFSpecimen Type
CSFSpecimen Minimum Volume
1.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| CSF | Refrigerated (preferred) | 28 days |
| Frozen | 28 days | |
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Adenylate kinase 5 IgG (AK5-IgG) is a marker intended for evaluating patients with autoimmune encephalitis, most often presenting as a non-paraneoplastic limbic encephalitis. Poor response to immunotherapy has been reported while there is no clear cancer association (non-paraneoplastic). AK5-IgG positive patients present with predominant severe amnestic syndrome, associated depression, and anxiety. Epilepsy is often absent at disease onset, however seizures may develop later.
Reference Values
Only orderable as part of a profile. For more information see:
-DMC2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
-EPC2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid
Negative
Day(s) Performed
Varies
Report Available
5 to 10 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255